Clinical Trials for Alnylam Pharmaceuticals

Explore 22 clinical trials worldwide

Showing 1-22 of 22 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Alnylam Pharmaceuticals

Clinical Trials (22)

NCT07181109
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
PHASE3Recruiting
11,000 participants
Started: Oct 24, 2025 · Completed: Oct 29, 2030
3 conditions2 sponsors30 locations
NCT07214727
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
PHASE1Not yet recruiting
50 participants
Started: Oct 9, 2025 · Completed: Mar 31, 2030
1 condition2 sponsors13 locations
NCT07052903
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
PHASE3Recruiting
1,250 participants
Started: Jul 2, 2025 · Completed: Nov 30, 2032
1 condition1 sponsor17 locations
NCT06845202
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
PHASE1/PHASE2Recruiting
144 participants
Started: Mar 3, 2025 · Completed: Aug 31, 2027
2 conditions1 sponsor18 locations
NCT06600321
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
PHASE1Recruiting
158 participants
Started: Dec 30, 2024 · Completed: Oct 31, 2027
2 conditions1 sponsor19 locations
NCT06679946
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
PHASE3Enrolling by invitation
700 participants
Started: Dec 3, 2024 · Completed: May 30, 2028
1 condition1 sponsor74 locations
NCT06659640
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
PHASE1/PHASE2Recruiting
120 participants
Started: Nov 11, 2024 · Completed: Jun 21, 2028
1 condition1 sponsor2 locations
NCT06585449
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
PHASE1Recruiting
54 participants
Started: Oct 14, 2024 · Completed: Jul 5, 2028
1 condition1 sponsor17 locations
NCT06393712
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
PHASE2Recruiting
200 participants
Started: May 17, 2024 · Completed: Nov 1, 2029
1 condition1 sponsor49 locations
NCT06360289
Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
N/ARecruiting
500 participants
Started: Apr 25, 2024 · Completed: Dec 1, 2027
2 conditions1 sponsor1 location
NCT06225544
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
PHASE2Recruiting
50 participants
Started: Apr 14, 2024 · Completed: Mar 1, 2025
5 conditions2 sponsors1 location
NCT06272487
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
PHASE2Active, not recruiting
375 participants
Started: Feb 29, 2024 · Completed: Dec 19, 2025
2 conditions1 sponsor193 locations
NCT05023889
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
EARLY_PHASE1Active, not recruiting
10 participants
Started: Aug 3, 2022 · Completed: Feb 25, 2026
5 conditions2 sponsors1 location
NCT05231785
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
PHASE1Recruiting
60 participants
Started: Feb 4, 2022 · Completed: Mar 28, 2029
1 condition1 sponsor8 locations
NCT04982393
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
N/ARecruiting
200 participants
Started: Dec 13, 2021 · Completed: Sep 1, 2028
1 condition1 sponsor30 locations
NCT04883905
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
N/ARecruiting
150 participants
Started: Apr 26, 2021 · Completed: Apr 1, 2027
1 condition1 sponsor29 locations
NCT04561518
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
N/ARecruiting
1,500 participants
Started: Nov 23, 2020 · Completed: Sep 1, 2030
2 conditions1 sponsor40 locations
NCT05577819
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
NARecruiting
515 participants
Started: Oct 2, 2020 · Completed: Dec 31, 2026
4 conditions5 sponsors1 location
NCT05040373
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
N/ARecruiting
10 participants
Started: Aug 1, 2020 · Completed: Oct 12, 2030
2 conditions1 sponsor7 locations
NCT04153149
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
PHASE3Active, not recruiting
655 participants
Started: Nov 26, 2019 · Completed: Dec 1, 2026
1 condition1 sponsor79 locations
NCT03997383
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
PHASE3Active, not recruiting
360 participants
Started: Sep 4, 2019 · Completed: Mar 1, 2027
1 condition1 sponsor67 locations
NCT03759379
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
PHASE3Active, not recruiting
164 participants
Started: Feb 14, 2019 · Completed: Oct 29, 2025
2 conditions1 sponsor53 locations